Aevi Genomic Medicine has expanded its collaboration with Kyowa Hakko Kirin with the signing of an option agreement for an early stage monoclonal antibody program in an ultra-orphan pediatric indication.   Together, the companies have developed a collaboration framework to advance preclinical programs into the clinic, leveraging Aevi Genomic Medicine’s expertise in rare and orphan pediatric diseases, and its ongoing collaboration with Children’s Hospital of Philadelphia (&#82...